Date: 2011-05-17
Type of information: Product acquisition
Compound: BL-7030
Company: BiolineRx (Israel) Algen BioPharmaceuticals (Israel)
Therapeutic area: Cancer - Oncology
Type agreement: rights acquisition
Action mechanism: BL-7030 is a vector targeted to epidermal growth factor receptors (EGFR) and is loaded with double stranded RNA.BL-7030 has unique elements that enable it to specifically penetrate cancer cells and destroy them. The molecule\'s specific recognition and binding to the EGFR target, a characteristic of various types of cancer, enhances the efficacy and safety of the treatment. To date, BL-7030 has demonstrated specific binding to the receptor target in cell culture and high efficacy against various types of cancer in animal models of human cancer. An important potential advantage of this treatment, demonstrated in animal models, is that low dosages of micrograms can be used (hundreds of times lower than dosages usually administered), leading to an increased lifespan and a decrease in tumor size in animals. In a number of animal studies with BL-7030, tumors were completely eliminated, with no adverse effects.
Disease:
Details: * On May 17, 2011, BioLineRx announced that it has acquired the rights to compound BL-7030, a novel molecule for targeted cancer therapy, from Algen, which received exclusive rights from Yissum, the Hebrew University of Jerusalem.
Financial terms:
Latest news:
